The biotechnology industry is characterized by high risk and high reward. Fraught with instability and uncertainty, biotechnology reflects the often-unpredictable nature of the underlying science.
Capital market investors, excited by the possibilities of blockbuster biotechnology products, remain increasingly skeptical of the daunting development, regulatory, insurance and financing risks. Intellectual property protection of biotechnology faces historic, new limitations and difficulties. The regulatory burden is forever increasing, and reimbursement has become a dominant consideration for drug development investors.
You need experienced lawyers who are committed to guiding you through a wide range of legal matters. Dentons eases the pressures you face; our multidisciplinary team of lawyers are scientifically savvy and driven to deliver innovative solutions. Many of our lawyers have advanced degrees in biotechnology-related disciplines. Others have relevant financial skills or knowledge of intellectual property matters. All of us bring skills and experience to work with you to determine your needs and meet them. By identifying and solving your biotechnology legal issues, we improve your focus on areas that attracted you to the sector—whether discovery, research, product development, business development or commercialization. Look to Dentons for innovative business and legal solutions across the biotechnology sector, including:
Our service can expand worldwide or contract to a local level, as required, from the laboratory and startup, to corporate governance, initial public offerings and beyond. That’s our commitment to you.
Singapore: Scams and cyber attacks – it can happen to any corporate entity. Nobody is immune to scams and cyber-attacks. With the increase in scammers’ levels of sophistication, their targets have also increased in scale. Scammers even routinely target multinational corporates and banks which have far more robust defences and highly trained personnel than the average SME. As such, the authors seek to suggest a quick response playbook that companies can consider adopting and for determining their responses during a time-sensitive period when faced with such issues.
On Tuesday December 27, 2011, the U.S. Food and Drug Administration (FDA) issued draft guidance to drug and device companies on responding to unsolicited requests for off-label information related to their FDA-approved or cleared products. The draft guidance covers both: 1) responding to requests made directly and privately to companies, and 2) requests made in public forums, including through emerging electronic media.
Global law firm Dentons advised the Board of Directors and shareholders of VRmagic on the sale of 77 percent of their shares in the company to the Swiss medical technology company Haag-Streit.
Global law firm Dentons has advised the Israeli biotech company Pluristem on a €50 million loan provided by the European Investment Bank (EIB). The financing is part of a cooperation agreement between the EIB and the Israel Innovation Authority, which aims to strengthen Israeli-EU cooperation in innovative research in the field of biotech, pharmaceutical research and public health.
Global law firm Dentons advised all shareholders of leading German multiplex cytometry provider Zellkraftwerk GmbH on the sale of their shares to Canopy Biosciences, a leading provider of gene editing and gene expression products and services. The transaction creates a “multi-omics” company, which combines genomic expertise and cell and tissue analysis, strengthening the strategic position of both companies.
View all press releases for Biotechnology Companies